Author Affiliations: Division of Cardiovascular Medicine (Dr Goldberger), Department of Internal Medicine (Drs Goldberger and Fagerlin), Robert Wood Johnson Foundation Clinical Scholars Program (Dr Goldberger), VA Ann Arbor Center for Clinical Management Research (Dr Fagerlin), and Center for Bioethics and Social Sciences in Medicine (Dr Fagerlin), University of Michigan Health System, Ann Arbor.
The clear benefits of implantable cardioverter-defibrillators (ICDs) in selected populations have been consistently demonstrated through landmark investigations for more than 2 decades.1 After initially demonstrating efficacy in secondary prophylaxis of sudden cardiac death (SCD),2 ICDs are now first-line therapy for primary prophylaxis of SCD in many patients with ischemic or nonischemic cardiomyopathy.3,4
Zachary D. Goldberger, Angela Fagerlin. ICDs—Increasingly Complex DecisionsComment on “Patient Preference in the Decision to Place Implantable Cardioverter-Defibrillators”. Arch Intern Med. 2012;172(14):1106–1107. doi:10.1001/archinternmed.2012.2660